Gysling E
Schweiz Med Wochenschr. 1976 Nov 13;106(46):1609-12.
In Switzerland the relative therapeutic value of various drugs (e.g. pyrazolone analgesics, phenacetin, clindamycine, clioquinol) is placed demonstrably higher than in Canada. In Canada, rare but possibly dangerous complications of drug therapy are considered to be of greater importance. Two factors might be responsible for these differences: 1. Compared with similar publications in Canada, drug advertisements in Swiss medical journals contain fewer warnings of untoward effects. This can be interpreted as an "information lag". 2. Since the link between an untoward effect and a drug is very difficult to establish with absolute certainty, it may be concluded that the drug is relatively inoffensive. This conclusion is drawn more often in Switzerland than in Canada. Uniformization of the way in which the physician is presented with information concerning untoward drug effects would be an important step towards the establishment of internationally accepted standards of drug therapeutic value.
在瑞士，各种药物（如吡唑酮类镇痛药、非那西丁、克林霉素、氯碘羟喹）的相对治疗价值明显高于加拿大。在加拿大，药物治疗中罕见但可能危险的并发症被认为更为重要。造成这些差异的因素可能有两个：1. 与加拿大类似的出版物相比，瑞士医学期刊上的药品广告中关于不良反应的警示较少。这可以被解释为一种“信息滞后”。2. 由于很难绝对确定地建立起不良反应与某种药物之间的联系，因此可能会得出该药物相对无害的结论。在瑞士，得出这一结论的情况比在加拿大更为常见。使医生获取有关药物不良反应信息的方式统一化，将是朝着建立国际公认的药物治疗价值标准迈出的重要一步。
